Metabolism and Disposition of Siponimod, a Novel Selective S1P1/S1P5 Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism.
Ulrike Glaenzel,Yi Jin,Robert Nufer,Wenkui Li,Kirsten Schroer,Sylvie Adam-Stitah,Sjoerd Peter van Marle,Eric Legangneux,Hubert Borell,Alexander David James,Axel Meissner,Gian Camenisch,Anne Gardin +12 more
Reads0
Chats0
TLDR
The selective inhibitor and recombinant enzyme results identified cytochrome P450 2C9 (CYP2C9) as the predominant contributor to the human liver microsomal biotransformation of siponimod, with minor contributions from CYP3A4 and other cyto Chrome P450 enzymes.Abstract:
Siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis. We investigated the absorption, distribution, metabolism, and excretion (ADME) of a single 10-mg oral dose of [14C]siponimod in four healthy men. Mass balance, blood and plasma radioactivity, and plasma siponimod concentrations were measured. Metabolite profiles were determined in plasma, urine, and feces. Metabolite structures were elucidated using mass spectrometry and comparison with reference compounds. Unchanged siponimod accounted for 57% of the total plasma radioactivity (area under the concentration-time curve), indicating substantial exposure to metabolites. Siponimod showed medium to slow absorption (median Tmax: 4 hours) and moderate distribution (Vz/F: 291 l). Siponimod was mainly cleared through biotransformation, predominantly by oxidative metabolism. The mean apparent elimination half-life of siponimod in plasma was 56.6 hours. Siponimod was excreted mostly in feces in the form of oxidative metabolites. The excretion of radioactivity was close to complete after 13 days. Based on the metabolite patterns, a phase II metabolite (M3) formed by glucuronidation of hydroxylated siponimod was the main circulating metabolite in plasma. However, in subsequent mouse ADME and clinical pharmacokinetic studies, a long-lived nonpolar metabolite (M17, cholesterol ester of siponimod) was identified as the most prominent systemic metabolite. We further conducted in vitro experiments to investigate the enzymes responsible for the oxidative metabolism of siponimod. The selective inhibitor and recombinant enzyme results identified cytochrome P450 2C9 (CYP2C9) as the predominant contributor to the human liver microsomal biotransformation of siponimod, with minor contributions from CYP3A4 and other cytochrome P450 enzymes.read more
Citations
More filters
Book ChapterDOI
Lessons from immunotherapies in multiple sclerosis
TL;DR: In this article , the use of advanced magnetic resonance imaging and biofluid markers has been strongly encouraged, since classifying patients according to the underlying biology will improve monitoring and treatment strategies.
Journal ArticleDOI
A Brief Review of Multiple Sclerosis Treatments
TL;DR: In this paper , the authors tried to classify based on how it is used on drugs used in the treatment of this disease, and at the same time the progress and achievement of new cases such as the use of monoclonal antibodies, despite all the progress made.
Book ChapterDOI
Design, conduct, and interpretation of human mass balance studies and strategies for assessing metabolites-in-safety testing (MIST) in drug development
Lysophospholipid (S1P) receptors in GtoPdb v.2023.1 Lysophospholipid (S1P) receptors in GtoPdb v.2023.1
Victoria A. Blaho,Jerold Chun,Deron R. Herr,Danielle Jones,Deepa Jonnalagadda,Yasuki Kihara,S. Burnham +6 more
TL;DR: S1P receptors are expressed throughout all mammalian organ systems as discussed by the authors , particularly S1P 1 , and their roles have been characterized through radioligand binding in heterologous networks.
Journal ArticleDOI
Disposition and Mass Balance of Etrasimod in Healthy Subjects and In Vitro Determination of the Enzymes Responsible for Its Oxidative Metabolism
D. Alexander Oh,Yong Tang,Ping Yi,Mohammad Bashir,Stephen English,Marie Croft,Anthony Blackburn,Kye Gilder,John S. Grundy +8 more
TL;DR: Etrasimod (APD334) is an investigational, once-daily, oral, selective sphingosine 1-phosphate receptor 1,4,5 modulator (S1P1, 4,5) in development for treatment of various immune-mediated inflammatory disorders as mentioned in this paper .
References
More filters
Journal Article
Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.
TL;DR: The results presented in this study provide useful information for the study of drug biotransformation in humans and for the basis of drug toxicities, carcinogenesis and teratogenesis.
Journal ArticleDOI
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Mehrdad Matloubian,Charles G. Lo,Guy Cinamon,Matthew J. Lesneski,Ying Xu,Volker Brinkmann,Maria L. Allende,Richard L. Proia,Jason G. Cyster +8 more
TL;DR: It is established that S1P1 is essential for lymphocyte recirculation and that it regulates egress from both thymus and peripheral lymphoid organs.
Journal ArticleDOI
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos,Ernst Wilhelm Radue,Paul O'Connor,Chris H. Polman,Reinhard Hohlfeld,Peter A. Calabresi,Krzysztof Selmaj,Catherine Agoropoulou,Malgorzata Leyk,Lixin Zhang-Auberson,Pascale Burtin +10 more
TL;DR: Both doses of oral fingolimod improved the relapse rate, the risk of disability progression, and end points on MRI and were superior to placebo with regard to MRI-related measures.
Journal ArticleDOI
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Jeffrey A. Cohen,Frederik Barkhof,Giancarlo Comi,Hans Peter Hartung,Bhupendra Khatri,Xavier Montalban,Jean Pelletier,Ruggero Capra,Paolo Gallo,Guillermo Izquierdo,Klaus Tiel-Wilck,Ana de Vera,James Jin,Tracy Stites,Stacy Wu,Shreeram Aradhye,Ludwig Kappos +16 more
TL;DR: This trial showed the superior efficacy of oral fingolimod with respect to relapse rates and MRI outcomes in patients with multiple sclerosis, as compared with intramuscular interferon beta-1a.
Journal ArticleDOI
The immune modulator FTY720 targets sphingosine 1-phosphate receptors.
Volker Brinkmann,Michael Davis,Christopher E. Heise,R. Albert,Sylvain Cottens,Robert Paul Hof,Christian Bruns,Eva Prieschl,Thomas Baumruker,Peter Hiestand,Carolyn An Foster,Markus Zollinger,Kevin R. Lynch +12 more
TL;DR: The results suggest that FTY720, after phosphorylation, acts through sphingosine 1-phosphate signaling pathways to modulate chemotactic responses and lymphocyte trafficking.
Related Papers (5)
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate.
Pál Gergely,Barbara Nuesslein-Hildesheim,Danilo Guerini,Volker Brinkmann,Martin Traebert,Christian Bruns,Shifeng Pan,Nathanael S. Gray,Klaus Hinterding,Nigel Graham Cooke,Andrea Groenewegen,A Vitaliti,Tobias Sing,O Luttringer,J Yang,Anne Gardin,N Wang,W J Crumb,M Saltzman,Mara Rosenberg,E Wallström +20 more